1937results about "Multivalent vaccine" patented technology

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and / or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

This disclosure relates to fusion proteins comprising one or more EBV polypeptides and a ferritin protein, and their use in eliciting antibodies against EBV.

The present invention provides vectors and / or nucleic acid constructs that encode one or more influenza A virus neuraminidase (NA) antigens. The present invention also provides vaccine against influenza A virus comprising such vectors and / or nucleic acid constructs. The present invention further provides methods of making and using the vaccines alone, or in combination with other protective agents.

The invention provides an H1N1 broad-spectrum mRNA (messenger ribonucleic acid) vaccine taking HA (hemagglutinin) and NA (neuraminidase) protein tandem as a target and a preparation method of the H1N1 broad-spectrum mRNA vaccine, and relates to the technical field of vaccine preparation, the amino acid sequence of the mRNA vaccine is shown as SEQ ID NO.1, and the nucleotide sequence of the mRNA vaccine is shown as SEQ ID NO.2, namely, the mRNA vaccine is obtained by connecting GGGSGGSGGGSGGGGS with conserved amino acid sequences of hemagglutinin HA and neuraminidase NA. The defects in the prior art are overcome, and the broad spectrum and the protection effect of the vaccine are improved, so that the vaccine can better cope with the immune escape of the latest variant in the future.

The invention provides a chimeric bivalent SFTSV (severe fever with thrombocytopenia syndrome virus) mRNA (messenger ribonucleic acid) vaccine, which is characterized in that the vaccine co-expresses an SFTSV envelope protein precursor GPC and a nucleoprotein NP in series through a flexible joint. Through humoral immunity, cellular immunity and challenge protection effect evaluation, the effectiveness of the mRNA vaccine provided by the invention is verified. Research results show that the prepared SFTSV mRNA vaccine can generate a good immune protection effect by only needing one mRNA, has the characteristics of simple industrial production, easy quality control and the like, and is an ideal choice of the SFTSV vaccine.

The present application provides an RNA encoding a varicella-zoster (VZV) glycoprotein E (gE) or a variant thereof, the RNA comprising a nucleotide sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence represented by any one of SEQ ID NO: 11-18. The eight mRNAs provided by the invention can translate in cells, the expression level of the generated VZV gE protein is high, and the mRNAs can induce a mouse to generate a high-titer gE specific IgG antibody in a manner of intramuscular injection into the body of the mouse through a preparation formed by encapsulating the lipidosome nanoparticles.

The present application relates to a polynucleotide molecule that can be used for preventing or treatment HPV infection-related diseases, and a pharmaceutical product, a pharmaceutical composition, or an mRNA vaccine comprising said polynucleotide.

The invention provides a composition useful to prepare influenza vaccine viruses, e.g., in the absence of helper virus, which includes internal viral segments from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and encodes a heterologous antigen.

Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

The invention provides a novel three-antigen HSV-2 adjuvant subunit vaccine as well as a preparation method and application thereof. The vaccine comprises herpes simplex virus recombinant protein and a composite adjuvant, the herpes simplex virus recombinant protein comprises extracellular domains of three proteins, namely HSV-2gE, gD and gC, wherein the amino acid sequences of the extracellular domains of the HSV-2gE, the gD and the gC are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3; and the composite adjuvant is composed of CpG oligodeoxynucleotide and QS-21. Experiments prove that by adding the composite adjuvant composed of CpG oligodeoxynucleotide and QS-21, the immunogenicity, in-vivo protectiveness, virus removal and other immune functions of the HSV-2 subunit vaccine can be remarkably improved; meanwhile, the vaccine is a cross immune protection vaccine of an HSV-2 virus strain and an HSV-1 virus strain.

Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

The present invention relates generally to nucleic acids comprising a plurality of polynucleotide sequences wherein each polynucleotide sequence of the plurality of polynucleotide sequences comprises a target sequence, a linker sequence and a self-assembly sequence, or a linker sequence, a target sequence, a linker sequence and a self-assembly sequence, or a combination thereof, wherein each polynucleotide sequence of the plurality of polynucleotide sequences is linked to a neighboring polynucleotide sequence of the plurality of polynucleotide sequences by a cleavage sequence, and wherein the nucleic acid further comprises a signal sequence upstream of one or more polynucleotide sequences of the plurality of polynucleotide sequences.

The invention discloses an H9N2 subtype avian influenza virus, the H9N2 subtype avian influenza virus is A / chick / Guangxi / C1228 / 2015 (H9N2), and the preservation number of the H9N2 subtype avian influenza virus is CGMCC (China General Microbiological Culture Collection Center) No.45222; or the H9N2 subtype avian influenza virus is A / quil / Guangxi / 210Q33 / 2015 (H9N2), and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 46091. The bivalent inactivated vaccine of CK / GX / C1228 / 15 with better antigenicity and the strain QL / GX / 210Q33 / 15 which has better antigenicity and is separated from quails in the live poultry market has a better protection effect on two different branches of H9N2 subtype avian influenza viruses, the lowest immune dose (0.3 mL) can reach the protection rate of 80% or above, and the generated effective protection antibody can last to 24W.

The present invention provides engineered soluble F proteins of paramyxoviruses, such as respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and human parainfluenza virus (hPIV). These engineered proteins are stabilized by specific modifications in the wild-type soluble F sequence, such as substitutions in the 023 chain and / or the introduction of engineered disulfide bonds in the 0 hairpin in the F1 subunit. The present invention also provides a nanoparticle vaccine comprising an engineered soluble F immunogen displayed on a self-assembled nanoparticle. The invention also provides methods of using such vaccine compositions in a variety of therapeutic applications, e.g., methods for preventing or treating viral infections, such as RSV, MPV, and PIV infections.

The invention belongs to the technical field of tumor vaccines, and particularly relates to an mRNA (messenger Ribonucleic Acid) vaccine for coding tumor antigen epitopes as well as a preparation method and application thereof. In order to overcome the defect of immune escape caused by insufficiency or loss of a single antigen, the invention provides an mRNA vaccine capable of simultaneously coding a plurality of tumor antigen epitopes, and the tumor antigen epitopes are selected from high-frequency mutation epitopes of human tumor driving genes, such as G12D, G12V and G12C mutations of RAS genes; the antigenic epitopes can be used for preparing antigenic epitopes related to common viruses of human tumors, such as HPV16E6 / E7, EBV LAMP1 or CMV pp65, and tumor high-expression carcino-embryonic antigen gene epitopes, such as MAGE-A4, NY-ESO-1, WT1, and the like. The mRNA vaccine is obtained by serially expressing a plurality of tumor antigen epitopes and encapsulating and delivering lipid nanoparticles. Experiments prove that the compound can effectively prevent and treat various tumors and has a wide application prospect.

The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.

The present disclosure relates to compositions and methods for vaccinating a subject against a variety of SARS-CoV-2 variants and other respiratory viruses, the compositions and methods involve preparing and delivering extracellular vesicles expressing on its surface an engineered spike protein, an engineered nucleocapsid protein, an engineered hemagglutinin protein, and / or an engineered respiratory syncytial virus pre-fusion or fusion (RSV F) protein. The invention also relates to compositions and methods for designing, preparing, making, formulating and / or using spike display, nucleocapsid display, hemagglutinin display and / or RSV F display vesicle vaccines, the spike display, nucleocapsid display, hemagglutinin display, and / or RSV F display vesicle vaccines are designed to elicit potent humoral and cellular immune responses against a variety of respiratory viruses and variants.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The present invention relates to polypeptide and peptide vaccine compositions and methods that reduce methane and / or hydrogen production in animals. The present invention also relates to the treatment of diseases that are associated with methanogens.

The present invention relates to Shigella outer membrane vesicles comprising at least one heterologous O-antigen, a recombinant Shigella bacterium comprising at least one heterologous O-antigen, methods for preparing the outer membrane vesicles or recombinant Shigella bacterium, plasmids for use in the methods, immunogenic compositions, vaccines and methods of treatment.

A lyophilized pharmaceutical composition for Staphylococcus Aureus vaccine and the method of generating the lyophilized pharmaceutical composition are provided. Also provided is a spray-freezed dried pharmaceutical composition for Staphylococcus Aureus vaccine and the method of generating the spray-freezed dried pharmaceutical composition.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.

The invention relates to an HSV-2 three-antigen subunit vaccine as well as a preparation method and application thereof, and belongs to the technical field of biology. The vaccine comprises an HSV-2 recombinant protein and a composite adjuvant, the HSV-2 recombinant protein comprises extracellular domains of three proteins, namely, HSV-2 gB2, HSV-2 gD2 and HSV-2 gE2; the composite adjuvant is composed of CpG oligodeoxynucleotide and an aluminum adjuvant. According to the HSV-2 three-antigen subunit vaccine, gB2, gD2 and gE2 proteins of HSV-2 serve as antigens, CpG oligodeoxynucleotide and an aluminum adjuvant serve as composite adjuvants, a BALB / c mouse is immunized in an intramuscular injection mode, high-level gB2, gD2 and gE2 specific IgG antibodies are successfully induced, and the neutralizing capacity of immune serum to an HSV-2 virus strain and the cross neutralizing capacity of immune serum to an HSV-1 virus strain are effectively improved.

The Human Immunodeficiency Virus (HIV) infection and recurrent infection prevention mRNA vaccine comprising epitopes of HIV-1 and HIV-2 viruses and their corresponding Nef proteins.

To provide a method for selecting a subject for whom the effect of a pharmaceutical composition for treating or preventing cancer can be expected.SOLUTION: A step of determining an expression level of WT1mRNA using a sample collected from a subject, and a step of providing an indicator that the subject is a subject for whom the pharmaceutical composition is expected to be effective when the expression level of WT1mRNA is less than or equal to or less than 10000 copies / μ gRNA.SELECTED DRAWING: None